Development of drug resistance in Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense. Treatment of human Africa trypanosomiasis with natural products (review)

International Journal of Molecular Medicine

Volumn 22, Issue 4, 2008, Pages 411-419

  Gehrig, Stefanie ^a   Efferth, Thomas ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

difluorornithine; Chemotherapy; Drug resistance; Human Africa trypanosomiasis; Melarsoprol; Natural products; Pentamidine; Pharmacognosy; Suramin; Trypanocidal activity; Trypanosoma brucei gambiense; Typanosoma brucei rhodesiense

Indexed keywords

ADENOSYLMETHIONINE DECARBOXYLASE; ANCISTROCLADIDINE; ANCISTROCLADUS LIKOKO EXTRACT; ANCISTROCLADUS TARZANIENSIS EXTRACT; ANCISTROLIKOKINE; ANCISTROTANZANINE; ANCISTROTECTORINE; ANTHRAQUINONE DERIVATIVE; ASCIDIDEMIN; DIMETHYLANCISTROCLADININE; DIONCOPHYLLEINE A; DNA; DNA TOPOISOMERASE; EFLORNITHINE; EMODIN; ISOQUINOLINE ALKALOID; LEPADIN; LOW DENSITY LIPOPROTEIN; MELARSOPROL; MULTIDRUG RESISTANCE PROTEIN; NATURAL PRODUCT; NUCLEOTIDE TRANSPORTER; ORNITHINE DECARBOXYLASE; ORTHO METHYL ANCISTROCLADININE; PANCRANINE; PENTAMIDINE; PLANT EXTRACT; SURAMIN; TERPENE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AFRICA SOUTH OF THE SAHARA; AFRICAN TRYPANOSOMIASIS; ANCISTROCLADUS LIKOKO; ANCISTROCLADUS TARZANIENSIS; ANTIBIOTIC RESISTANCE; ANTIPROTOZOAL ACTIVITY; BRAIN DISEASE; CARYOPHYLLACEAE; DEATH; DRUG APPROVAL; DRUG POTENCY; DRUG RESEARCH; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; INHIBITION KINETICS; LIPID TRANSPORT; PRIORITY JOURNAL; REVIEW; TRYPANOSOMA BRUCEI; TRYPANOSOMA GAMBIENSE; TRYPANOSOMA RHODESIENSE;

ANIMALS; BIOLOGICAL PRODUCTS; DRUG RESISTANCE; HUMANS; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMA BRUCEI RHODESIENSE; TRYPANOSOMIASIS, AFRICAN;

EID: 54049122193     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijmm_00000037     Document Type: Review

References (65)

1. Tagboto S and Townson S: Antiparasitic properties of medical plants and other naturally occurring products. Adv Parasitol 50: 199-295, 2001.
2. Kayser O and Kiderlen AF: Delivery strategies for antiparasitics. Expert Opin Investig Drugs 12: 197-207, 2003.
3. Kayser O, Kiderlen AF and Croft SL: Natural Products as antiparasitic drugs. Parasitol Res 90 (Suppl 2): 55-62, 2003.
4. Holzgrabe U and Bechthold A: Paradigmenwechsel in der Entwicklung antiinfektiver Chemotherapeutika. J Chemother 8: 69-78, 1999.
5. Barrett MP: The fall and rise of sleeping sickness. Lancet 353: 1113-1114, 1999.
6. Tanowitz HB, Wittner M, Werner C, Weiss LM, Kirchhoff LV and Bacchi C: Trypanosomes. In: Encyclopedia of Microbiology. Lederberg J (ed). Vol. 4 Q-Z, 2nd edition, Academic Press, London, pp725-741, 2000.
7. World Health Organisation: African trypanosomiasis (sleeping sickness). Fact sheet No. 259 WHO, 2006.
8. Centers of Disease Control and Prevention, CDC's Division of Parasitic Diseases: African trypanosomiasis. http://www.dpd.cdc.gov/dpdx/HTML/ TrypanosomiasisAfrican.htm, January 14th, 2008.
9. Ali V and Nozaki T: Current therapeutics, their problems, and sulfur- containing-amino-acid metabolism as a novel target against infections by 'amitochondriate' protozoan parasites. Clin Microbiol Rev 20: 164-187, 2007.
10. Shapiro TA and Englund PT: The structure and replication of kinetoplast DNA. Annu Rev Microbiol 49: 117-143, 1995.
11. Opperdoes FR and Michels PAM: Enzymes of carbohydrate metabolism as potential drug targets. Int J Parasitol 31: 482-490, 2001.
12. Penketh PG and Klein RA: Hydrogen peroxide metabolism in Trypanosoma brucei. Mol Biochem Parasitol 20: 111-121, 1986.
13. Fairlamb A, Blackburn P, Ulrich P, Chait B and Cerami A: Trypanothione: a novel bis (glutathionyl) spermidine cofactor for glutathione reductase in trypanosomatids. Science 22: 1485-1487, 1985.
14. Bacchi CJ and Yarlett N: Effects of antagonists of polyamine metabolism on African trypanosomes. Acta Trop 54: 225-236, 1993.
15. Mäser P, Lüscher A and Kaminsky R: Drug transport and drug resistance in African trypanosomes. Drug Resist Updat 6: 281-290, 2003.
16. Fish WR, Looker DL, Marr JJ and Berens RL: Purine metabolism in the bloodstream fonns of Trypanosoma gambiense and Trypanosoma rhodesiense. Biochim Biophys Acta 719: 223-231, 1982.
17. Coppens I and Courtoy PJ: The adaptative mechanisms of Trypanosoma brucei for sterol homeostasis in its different life-cycle environments. Annu Rev Microbiol 54: 129-156, 2000.
18. Matovu E, Stewart ML, Geiser F, Brun R, Mäser P, Wallace LJ, Burchmore RJ, Enyaru JC, Barrett MP, Kaminsky R, Seebeck T and de Koning HP: The mechanisms of arsenical and diamidine uptake and resistance in Trypanosoma brucei. Eukaryot Cell 2: 1003-1008, 2003.
19. Delespaux V and de Koning HP: Drugs and drug resistance in African trypanosomiasis. Drug Resist Updat 10: 30-50, 2007.
20. Carter NS and Fairlamb AH: Arsenical-resistant trypanosomes lack an unusual adenosine transporter. Nature 361: 173-175, 1993.
21. de Koning HP and Jarvis SM: Adenosine transporters in bloodstream forms of Trypanosoma brucei brucei: substrate recognition motifs and affinity for trypanocidal drugs. Mol Pharmacol 56: 1162-1170, 1999.
22. Fox KR, Sansom CE and Stevens MF: Footprinting studies on the sequence-selective binding of pentamidine to DNA. FEBS Lett 266: 150-154, 1990.
23. Edwards KJ, Jenkins TC and Neidle S: Crystal structure of a pentamidine-oligonucleotide complex: implications for DNA-binding properties. Biochemistry 31: 7104-7109, 1992.
24. Bitonti AJ, Dumont JA and McCann PP: Characterization of Trypanosoma brucei brucei S-adenosylmethionine decarboxylase and its inhibition by Berenil, pentamidine and methylglyoxal bis (guanylhydrazone). Biochem J 237: 685-689, 1986.
25. Vansterkenburg ELM, Coppens I, Wilting J, Bos OJM, Fischer MJE, Janssen LHM and Opperdoes FR: The uptake of the trypanocidal. drug Suramin in combination with low-density lipoproteins by Trypanosoma brucei and its possible mode of action. Acta Trop 54: 237-250, 1993.
26. Pépin J and Milord F: The treatment of human African trypanosomiasis. Adv Parasitol 33: 1-47, 1994.
27. Wang CC: Molecular mechanisms and therapeutic approaches to the treatment of African trypanosomiasis. Annu Rev Pharmacol Toxicol 35: 93-127, 1995.
28. Blum J, Nkunku S and Burri C: Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis. Trop Med Int Health 6: 390-400, 2001.
29. Whittle HC and Pope HM: Febrile response to treatment in Gambian sleeping sickness. Ann Trop Med Parasitol 66: 7-14, 1974.
30. Fairlamb AH, Henderson GB and Cerami A: Trypanothione is the primary target for arsenical drugs against African trypanosomes. Proc Natl Acad Sci USA 86: 2607-2611, 1989.
31. Cunningham ML, Zvelebil MJ and Fairlamb AH: Mechanism of inhibition of trypanothione reductase and glutathione reductase by trivalent organic arsenicals. Eur J Biochem 221: 285-295, 1994.
32. Kuzoe FAS: Current situation of African trypanosoiasis. Acta Trop 54: 153-162, 1993.
33. Iten M, Matovu E, Brun R and Kaminsky R: Innate lack of susceptibility of Ugandan Trypanosoma brucei rhodesiense to DL-alpha-difluoromethylornithine (DFMO). Ann Trop Med Parasitol 46: 190-194, 1994.
34. Iten M, Mett H, Evans A, Enyaru JC, Brun R and Kaminsky R: Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to D,L-alpha-difluoromethylornithine. Antimicrob Agents Chermother 41: 1922-1925, 1997.
35. Mamont PS, Duchesne MC, Grove J and Bey P: Anti-proliferative properties of DL-alpha-difluoromethylomithine in cultured cells. A consequence of the irreversible inhibition of ornithine decarboxylase. Biochem Biophys Res Commun 81: 58-66, 1987.
36. Poulin R, Lu L, Ackermann B, Bey P and Pegg AE: Mechanism of the irreversible inactivation of mouse ornithine decarboxylase by alpha-difluoromethylornithine. Characterisation of sequences at the inhibitor and coenzyme binding sites. J Biol Chem 267: 150-158, 1992.
37. Bacchi CJ, Garofano J, Ciminelli M, Rattendi D, Goldberg B, McCann PP and Yarlett N: Resistance to DL-alphadifluoromethylornithine by clinical isolates of Trypanosoma brucei rhodesiense - role of S-adenosylmethionine. Biochem Pharmacol 46: 471-481, 1993.
38. Weber JT and Courvalin P: An empty quiver: antimicrobial drugs and resistance. Emerg Infect Dis 11: 791-793, 2005.
39. Mäser P, Sütterlin C, Kralli A and Kaminsky R: A nucleoside transporter from Trypanosoma brucei involved in drug resistance. Science 285: 242-244, 1999.
40. Shahi SK, Krauth-Siegel RL and Clayton CE: Overexpression of the putative thiol conjugate transporter TbMRPA causes melarsoprol resistance in Trypanosoma brucei. Mol Microbiol 43: 1129-1138, 2002.
41. Mäser P and Kaminsky R: Identification of three ABC transporter genes in Trypanosoma brucei spp. Parasitol Res 84: 106-111, 1998.
42. Keppler D, Leier I and Jedlitschky G: Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2. Biol Chem 378: 787-791, 1997.
43. Barrett MP, Mottram JC and Coombs GH: Recent advances in identifying and validating drug targets in trypanosomes and leishmanias. Trends Microbiol 7: 82-88, 1999.
44. Tasdemir D, Kaiser M, Brun R, Yardely V, Schmidt TJ, Tosun F and Rüedi P: Antitrypanosomal and antileishmanial activities of flavonoids and their analogues: in vitro, in vivo, structure-activity relationship, and quantitative structure-activity relationship studies. Antimicrob Agents Chemother 50: 1352-1364, 2006.
45. Hoet S, Opperdoes F, Brun R and Quetin-Leclercq J: Natural products active against African trypanosomes: a step towards new drugs. Nat Prod Rep 21: 353-364, 2004.
46. Bringmann G, Saeba W, Rückert M, Miesa J, Michela M, Mudogob V and Brunc R: Ancistrolikokine D, a 5,8′-coupled naphthylisoquinoline alkaloid, and related natural products from Ancistrocladus likoko. Phytochemistry 62: 631-636, 2003.
47. Bringmann G, Dreyer M, Faber JH, Dalsgaard PW, Staerk D, Jaroszewski JW, Ndangalasi H, Mbago F, Brun R and Christensen SB: Ancistrotanzanine C and related 5,1′- and 7,3′-coupled naphthylisoquinoline alkaloids from Ancistrocladus tanzaniensis. J Nat Prod 67: 743-748, 2004.
48. Bringmann G, Dreyer M, Kopff H, Rischer H, Wohlfarth M, Hadi HA, Brun B, Meimberg H and Heubl G: ent-Dioncophylleine A and related dehydrogenated naphthylisoquinoline alkaloids, the first Asian dioncophyllaceae-type alkaloids, from the 'new' plant species Ancistrocladus benomensis. J Nat Prod 68: 686-690, 2005.
49. Labraña J, Machocho AK, Kricsfalusy V, Brun R, Codina C, Viladomata F and Bastida J: Alkaloids from Narcissus angustifolius subsp. transcarpathicus (Amaryllidaceae). Phytochemistry 60: 847-852, 2002.
50. Wright AD, Goclik E, König GM and Kaminsky R: Lepadins D-F: antiplasmodial and antitrypanosomal decahydroquinoline derivatives from the tropical marine tunicate Didemnum sp. J Med Chem 45: 3067-3072, 2002.
51. Copp RB, Kayser O, Brun R and Kiderlen AF: Antiparasitic activity of marine pyridoacridone alkaloids related to the ascididemins. Planta Med 69: 527-531, 2003.
52. Mbwambo ZH, Apers S, Moshi MJ, Kapingu MC, Van Miert S, Claeys M, Brun R, Cos P, Pieters L and Vlietinck A: Anthranoid compounds with antiprotozoal activity from Vismia orientalis. Planta Med 70: 706-710, 2004.
53. Weniger B, Vonthron-Sénécheaun C, Kaiser M, Brun R and Anton R: Comparative antiplasmodial, leishmanicidal and antitrypanosomal activities of several biflavonoids. Phytomedicine 13: 176-180, 2006.
54. Wright AD, Papendorf O and König GM: Ambigol C and 2,4-dichlorobenzoic acid, natural products produced by the terrestrial cyanobacterium Fischerella ambigua. J Nat Prod 68: 459-461, 2005.
55. Gertsch J, Tobler RT, Brun R, Sticher O and Heilmann J: Antifungal, antiprotozoal, cytotoxic and piscicidal properties of Justicidin B and a new arylnaphthalide lignan from Phyllanthus piscatorum. Planta Med 69: 420-424, 2003.
56. Moideen VSK, Houghton PJ, Rock P, Croft SL and Aboagye-Nyame F: Activity of extracts and naphthoquinones from Kigelia pinnata against Trypanosoma brucei brucei and Trypanosonia brucei rhodesiense. Planta Med 65: 536-540, 1999.
57. Tasdemir D, Brun R, Franzblau SG, Sezgin Y and Calís I: Evaluation of antiprotozoal and antimycobacterial activities of the resin glycosides and the other metabolites of Scrophularia cryptophila. Phytomedicine 15: 209-215, 2008.
58. Tasdemir D, Güner ND, Perozzo R, Brun R, Dönmez AA, Calís I and Rüedi P: Anti-protozoal and plasmodial FabI enzyme inhibiting metabolites of Scrophularia lepidota roots. Phytochemistry 66: 355-362, 2005.
59. Calís I, Koyunoglu S, Yesilada A, Brun R, Rüedi P and Tasdemir D: Antitrypanosomal cycloartane glycosides from Astragalus baibutensis. Chem Biodivers 3: 923-929, 2006.
60. Schmidt TJ, Brun R, Willuhn G and Khalid SA: Anti-trypanosomal activity of helenalin and some structurally related sesquiterpene lactones. Planta Med 68: 750-751, 2002.
61. Hay AE, Ioset JR, Ahua KM, Diallo D, Brun R and Hostettmann K: Limonoid orthoacetates and antiprotozoal compounds from the roots of Pseudocedrela kotschyi. J Nat Prod 70: 9-13, 2007.
62. Senn M, Gunzenhauser S, Brun R and Séquin U: Antiprotozoal polyacetylenes from the Tanzanian medicinal plant Cussonia zimmermannii. J Nat Prod 70: 1565-1569, 2007.
63. Tasdemir D, Topatoglu B, Perozzo R, Brun R, O'Neill R, Carballeira. NM, Zhang X, Tonge PJ, Linden A and Rüedi P: Marine natural products from the Turkish sponge Agelas oroides that inhibit the enoyl reductases from Plasmodium falciparum, Mycobacterium tuberculosis and Escherichia coli. Bioorg Med Chem 15: 6834-6845, 2007.
64. Lun ZR, Burri C, Menzinger M and Kaminsky R: Antiparasitic activity of diallyl trisulfide (Dasuansu) on human and animal pathogenic protozoa (Trypanosoma sp., Entamoeba histolytica and Giardia lamblia) in vitro. Ann Soc Belg Med Trop 74: 51-59, 1974.
65. Nok AJ, Williams S and Onyenekwe PC: Allium sativum-induced death of African trypanosomes. Parasitol Res 82: 634-637, 1996.